STO:RAY-B
RaySearch Laboratories AB (publ) · STO · Healthcare · SEK · FY for 2025
Figures on this page computed 2026-11-08 13:23 UTC
Last close
n/aSEK
Market data
26.6xP/E
Price / Earnings per Share (diluted)
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- SEK
- computed
- Computed from the filing for 2025
26.2%ROIC
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- SEK
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
- Computed from the filing for 2025
16.9%Net margin
Net Income / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- SEK
- Computed from the filing for 2025
- Computed from the filing for 2025
26.7%FCF margin
Free Cash Flow / Revenue x 100
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- SEK
- Computed from the filing for 2025
- Computed from the filing for 2025
0.40Debt/equity
Total Debt / Shareholders' Equity
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- SEK
- Computed from the filing for 2025
- Computed from the filing for 2025
1.7%Dividend yield
- Source
- computed
- Taken on
- 2026-11-08
- Reported in
- SEK
- computed
6 of 6 traits placed on the market's range. Nothing sits below its sector's middle.
Ten years as a story
lens 9 of 9We hold no filed year for this company, so there is nothing to read.
Nothing is drawn in its place. The other lenses are unaffected.